<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211831</url>
  </required_header>
  <id_info>
    <org_study_id>URO-902-2001</org_study_id>
    <nct_id>NCT04211831</nct_id>
  </id_info>
  <brief_title>URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence</brief_title>
  <official_title>An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902
      24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with
      placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up
      to 48 weeks post-dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline at Week 12 in average daily number of Urge Urinary Incontinence (UUI) episodes</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any adverse event</measure>
    <time_frame>up to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Overactive Bladder With Urge Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Cohort 1: URO-902 24 mg; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: URO-902 48 mg; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either a single treatment of URO-902 48 mg or matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URO-902</intervention_name>
    <description>intradetrusor injection</description>
    <arm_group_label>Cohort 1: URO-902 24 mg; Placebo</arm_group_label>
    <arm_group_label>Cohort 2: URO-902 48 mg; Placebo</arm_group_label>
    <other_name>hMaxi-K</other_name>
    <other_name>pVAX/hSlo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intradetrusor injection</description>
    <arm_group_label>Cohort 1: URO-902 24 mg; Placebo</arm_group_label>
    <arm_group_label>Cohort 2: URO-902 48 mg; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has symptoms of Overactive Bladder (OAB) (frequency and urgency) with Urge
             Urinary Incontinence (UUI) for a period of at least 6 months prior to screening.

          -  Participant experiences ≥ 1 episode of UUI per day.

          -  Participant has not been adequately managed with ≥ 1 oral or transdermal pharmacologic
             therapies for the treatment of their OAB symptoms.

        Exclusion Criteria:

          -  Participant has symptoms of OAB due to any known neurological reason (e.g., spinal
             cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease,
             Parkinson's disease, etc).

          -  Participant has a predominance of stress incontinence in the opinion of the
             investigator, determined by participant history.

          -  Participant currently uses or plans to use medications or therapies to treat symptoms
             of OAB, including nocturia.

          -  Participants who have previously been treated with onabotulinumtoxinA for urological
             indications within 12 months of starting the Screening Bladder Diary, or any other
             toxin for urological indications, regardless of when treated (participants treated
             with onabotulinumtoxinA or other toxins for non-urological indications are eligible,
             regardless of when treated)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JP Nicandro, PharmD</last_name>
    <phone>833-219-5557</phone>
    <email>clinicaltrials@urovant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coastal Clinical Research Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri Valley Urology Medical Group</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oakland University Wm. Beaumont School of Medicine - Beaumont Health Center</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Urology Group, LLC</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Physician PC / Western New York Urology Associates</name>
      <address>
        <city>Cheektowaga</city>
        <state>New York</state>
        <zip>14225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accumed Research Associates - ClinEdge - PPDS</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Urology &amp; Urogynecology Associates</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>URO-902</keyword>
  <keyword>hMaxi-K</keyword>
  <keyword>pVAX/hSlo</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urge Urinary Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

